Univariate analysis for baseline prognostic factors of survival
| Prognostic factor . | PFS . | OS . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Male | 1.3 (0.6-2.7) | .53 | 0.7 (0.2-2.3) | .60 |
| Age ≥50 y | 1.8 (0.6-5.6) | .18 | 2.2 (0.4-11.4) | .23 |
| Mixed cellularity | 0.8 (0.3-2.2) | .68 | 1.1 (0.2-4.8) | .92 |
| Presence of B symptoms | 2.9 (1.3-6.7) | .0035 | 4.6 (1.3-15.6) | .006 |
| ≥4 Involved sites | 2.7 (0.7- 9.5) | .028 | 4.7 (0.7-31.5) | .006 |
| Bulk mediastinum (M/T ≥ 0.35) | 0.9-5.7 | .026 | 2.3 (0.6-8.9) | .13 |
| TMTV >147 cm3 | 5.2 (1.8-14.7) | <.0001 | 7.2 (1.6-33.4) | .0001 |
| U EORTC | 5.7 (2.7-12.3) | .0013 | NR | .0039 |
| U GHSG | 2.8 (1.3-6.3) | .046 | 5.3 (1.6-17.6) | .075 |
| U NCCN | 3.6 (1.7-7.9) | .011 | 6.7 (2.1-21.6) | .034 |
| Positive iPET2 (DS 4-5) | 12 (2.3-63.7) | <.0001 | 13.2 (1.4-128.3) | <.0001 |
| Prognostic factor . | PFS . | OS . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Male | 1.3 (0.6-2.7) | .53 | 0.7 (0.2-2.3) | .60 |
| Age ≥50 y | 1.8 (0.6-5.6) | .18 | 2.2 (0.4-11.4) | .23 |
| Mixed cellularity | 0.8 (0.3-2.2) | .68 | 1.1 (0.2-4.8) | .92 |
| Presence of B symptoms | 2.9 (1.3-6.7) | .0035 | 4.6 (1.3-15.6) | .006 |
| ≥4 Involved sites | 2.7 (0.7- 9.5) | .028 | 4.7 (0.7-31.5) | .006 |
| Bulk mediastinum (M/T ≥ 0.35) | 0.9-5.7 | .026 | 2.3 (0.6-8.9) | .13 |
| TMTV >147 cm3 | 5.2 (1.8-14.7) | <.0001 | 7.2 (1.6-33.4) | .0001 |
| U EORTC | 5.7 (2.7-12.3) | .0013 | NR | .0039 |
| U GHSG | 2.8 (1.3-6.3) | .046 | 5.3 (1.6-17.6) | .075 |
| U NCCN | 3.6 (1.7-7.9) | .011 | 6.7 (2.1-21.6) | .034 |
| Positive iPET2 (DS 4-5) | 12 (2.3-63.7) | <.0001 | 13.2 (1.4-128.3) | <.0001 |
NR, not reached.